Home LiteratureArticle Details
PMID: 19448659 Published · ppublish English Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Review

HIV-1 and influenza antibodies: seeing antigens in new ways.

Nature immunology ·Vol. 10 ·No. 6 ·2009-06-00 ·Pages 573-8

Kwong PD, Wilson IA

Abstract

New modes of humoral recognition have been identified by studies of antibodies that neutralize human immunodeficiency virus type 1 and influenza A viruses. Understanding how such modes of antibody-antigen recognition can occur in the context of sophisticated mechanisms of humoral evasion has implications for the development of effective vaccines. Here we describe eight modes of antibody recognition first observed with human immunodeficiency virus type 1. Similarities to four of these modes have been identified with antibodies to a conserved 'stem' epitope on influenza A viruses. We outline how each of these different modes of antibody recognition is particularly suited to overcoming a specific viral evasion tactic and assess potential routes of re-elicitation in vaccine settings.

MeSH Terms
AIDS Vaccines/immunology Antibodies, Viral/immunology Antigen-Antibody Reactions HIV Antigens/immunology HIV-1/immunology Humans Influenza A virus/immunology Influenza Vaccines/immunology Influenza, Human/immunology Models, Biological
Chemicals
AIDS Vaccines Antibodies, Viral HIV Antigens Influenza Vaccines
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Kwong Peter D
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. pdkwong@nih.gov
Wilson Ian A
References (60)
60 references, click to expand
  1. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.
    J Virol. 2005 Apr;79(8):5232-7 PMID: 15795308
  2. Zernike phase contrast electron microscopy of ice-embedded influenza A virus.
    J Struct Biol. 2008 May;162(2):271-6 PMID: 18313941
  3. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.
    J Mol Biol. 2008 Jan 25;375(4):969-78 PMID: 18068724
  4. New antivirals and drug resistance.
    Annu Rev Biochem. 2009;78:95-118 PMID: 19254207
  5. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.
    Nature. 2009 Apr 2;458(7238):636-40 PMID: 19287373
  6. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
    Nature. 1996 Nov 14;384(6605):179-83 PMID: 8906795
  7. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120.
    Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2706-11 PMID: 14981267
  8. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors.
    Nature. 2008 Sep 25;455(7212):532-6 PMID: 18716625
  9. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses.
    PLoS Pathog. 2009 Mar;5(3):e1000350 PMID: 19300497
  10. Evolutionary and immunological implications of contemporary HIV-1 variation.
    Br Med Bull. 2001;58:19-42 PMID: 11714622
  11. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
    J Virol. 2007 Jun;81(12):6548-62 PMID: 17409160
  12. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.
    AIDS. 2009 Mar 13;23(5):639-41 PMID: 19242316
  13. Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors.
    Curr Opin HIV AIDS. 2009 Mar;4(2):112-7 PMID: 19339949
  14. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
    J Virol. 1993 Nov;67(11):6642-7 PMID: 7692082
  15. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.
    Science. 2003 Jun 27;300(5628):2065-71 PMID: 12829775
  16. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody.
    Nat Struct Mol Biol. 2006 Aug;13(8):740-7 PMID: 16862157
  17. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.
    Nature. 1985 Jul 4-10;316(6023):69-72 PMID: 2989706
  18. Rapid evolution of the neutralizing antibody response to HIV type 1 infection.
    Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9 PMID: 12644702
  19. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.
    Nature. 2002 Dec 12;420(6916):678-82 PMID: 12478295
  20. Broad HIV-1 neutralization mediated by CD4-binding site antibodies.
    Nat Med. 2007 Sep;13(9):1032-4 PMID: 17721546
  21. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.
    J Virol. 2003 Oct;77(19):10557-65 PMID: 12970440
  22. Antibody recognition of a highly conserved influenza virus epitope.
    Science. 2009 Apr 10;324(5924):246-51 PMID: 19251591
  23. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.
    J Virol. 2009 Jan;83(2):757-69 PMID: 18987148
  24. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry.
    Cell. 1999 Mar 5;96(5):667-76 PMID: 10089882
  25. Antibody repertoire development in camelids.
    Dev Comp Immunol. 2006;30(1-2):187-98 PMID: 16051357
  26. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.
    Cell. 1986 Jun 6;45(5):637-48 PMID: 2423250
  27. Core structure of gp41 from the HIV envelope glycoprotein.
    Cell. 1997 Apr 18;89(2):263-73 PMID: 9108481
  28. Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon.
    Nature. 1996 Sep 26;383(6598):350-4 PMID: 8848050
  29. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.
    J Virol. 1994 Jun;68(6):4031-4 PMID: 7514684
  30. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Nature. 1998 Jun 18;393(6686):705-11 PMID: 9641684
  31. The canyon hypothesis.
    Viral Immunol. 1989 Fall;2(3):143-61 PMID: 2560913
  32. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses.
    Nat Struct Mol Biol. 2009 Mar;16(3):265-73 PMID: 19234466
  33. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
    J Virol. 2004 Dec;78(23):13232-52 PMID: 15542675
  34. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen.
    Blood. 2001 Feb 15;97(4):1023-6 PMID: 11159532
  35. Structural definition of a conserved neutralization epitope on HIV-1 gp120.
    Nature. 2007 Feb 15;445(7129):732-7 PMID: 17301785
  36. Antigenic conservation and immunogenicity of the HIV coreceptor binding site.
    J Exp Med. 2005 May 2;201(9):1407-19 PMID: 15867093
  37. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells.
    Cell. 2000 Mar 3;100(5):587-97 PMID: 10721995
  38. Antibody vs. HIV in a clash of evolutionary titans.
    Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):14943-8 PMID: 16219699
  39. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor.
    Nature. 2008 Jul 10;454(7201):177-82 PMID: 18615077
  40. Molecular architecture of native HIV-1 gp120 trimers.
    Nature. 2008 Sep 4;455(7209):109-13 PMID: 18668044
  41. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies.
    Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):5986-91 PMID: 18413603
  42. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
    J Virol. 2004 Oct;78(19):10724-37 PMID: 15367639
  43. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D.
    Structure. 2004 Feb;12(2):193-204 PMID: 14962380
  44. Structure-based antigen design: a strategy for next generation vaccines.
    Trends Biotechnol. 2008 Dec;26(12):659-67 PMID: 18977045
  45. [An approach the quantitative determination of the area of glycoprotein spikes at the surface of enveloped viruses].
    Mol Biol (Mosk). 2008 Nov-Dec;42(6):1093-6 PMID: 19140331
  46. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.
    J Virol. 1993 May;67(5):2552-8 PMID: 7682624
  47. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys.
    Nat Med. 2009 Aug;15(8):901-6 PMID: 19448633
  48. Antibody neutralization and escape by HIV-1.
    Nature. 2003 Mar 20;422(6929):307-12 PMID: 12646921
  49. Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.
    J Virol. 2009 May;83(10):5077-86 PMID: 19264769
  50. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion.
    Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17736-41 PMID: 19004788
  51. Antibody repertoire development in cartilaginous fish.
    Dev Comp Immunol. 2006;30(1-2):43-56 PMID: 16146649
  52. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.
    Science. 2001 Aug 10;293(5532):1155-9 PMID: 11498595
  53. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120.
    Cell. 2003 Jul 25;114(2):161-70 PMID: 12887918
  54. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4.
    Science. 2007 Sep 28;317(5846):1930-4 PMID: 17901336
  55. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
    J Immunol. 2007 Apr 1;178(7):4424-35 PMID: 17372000
  56. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.
    J Virol. 2003 May;77(10):5889-901 PMID: 12719582
  57. Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen.
    J Mol Biol. 2003 Jan 10;325(2):337-54 PMID: 12488099
  58. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.
    J Virol. 1993 Aug;67(8):4557-65 PMID: 8331723
  59. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.
    J Virol. 2009 Jan;83(1):188-99 PMID: 18922865
  60. Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery.
    Int Rev Immunol. 2009;28(1):69-92 PMID: 19241254
Article Info
Journal
Nature immunology
Abbr.
Nat Immunol
ISSN
1529-2916
DOI
10.1038/ni.1746
Email
pdkwong@nih.gov
Published
2009-06-00
Pages
573-8
Language
English
Region
United States
NLM ID
100941354
PMCID
PMC2796958
Subset
IM
Grants
Intramural NIH HHS · Z99 AI999999 · United States
External Links
PubMed source DOI: 10.1038/ni.1746 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2